Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24730818 | 1.00 | MAPKAPK2 (0.34) | MAPKAPK2RPS6KA3ALOX5TSHRIDO1 | |
| SCHEMBL34469210 | 1.00 | MAPKAPK2 (0.34) | MAPKAPK2RPS6KA3ALOX5TSHRIDO1 | |
| SCHEMBL17801738 | 0.69 | ALOX5 (0.35) | MAPKAPK2RPS6KA3ALOX5TSHRSCN9A | |
| SCHEMBL22759729 | 0.68 | ALOX5 (0.39) | ALOX5TSHRHRH3 | |
| SCHEMBL24730819 | 0.67 | ALOX5 (0.37) | ALOX5SCN9A | |
| SCHEMBL2316760 | 0.66 | ALDH1A1 (0.47) | MAPKAPK2RPS6KA3IDO1CDC7 | |
| SCHEMBL21738400 | 0.65 | MAPKAPK2 (0.32) | MAPKAPK2RPS6KA3HRH3 | |
| SCHEMBL24731156 | 0.64 | — | — | |
| SCHEMBL24730664 | 0.64 | — | — | |
| SCHEMBL24731061 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119110804-A | KRAS modulators and uses thereof | 光达治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022247770-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海璎黎药业有限公司 | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MAPKAPK2 232/4885RPS6KA3 1671/4885ALOX5 4830/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MAPKAPK2 293/4885RPS6KA3 2022/4885ALOX5 4811/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MAPKAPK2 648/4885RPS6KA3 683/4885ALOX5 4280/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MAPKAPK2 293/4885RPS6KA3 2022/4885ALOX5 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.